Allo HSCT Using RIC and PTCy for Hematological Diseases
Status:
Not yet recruiting
Trial end date:
2028-10-22
Target enrollment:
Participant gender:
Summary
This is a Phase II study following subjects proceeding with our Institutional
non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative
regimen followed by a related, unrelated, or partially matched family donor stem cell
infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.